Recent advances in ocular graft-versus-host disease

Cheng, Xianjing; Huang, Ruihao; Huang, Shiqin; Fan, Wenting; Ren, Yuan; Wang, Xiaoqi; Zhang, Xi

doi:10.3389/fimmu.2023.1092108

Cited by 8 publications

(3 citation statements)

References 154 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent evidence suggests that recruited fibroblasts may either derive from circulating donor-derived precursors or may arise from local epithelial to mesenchymal transition [ 73 , 74 ]. Regardless of their source, the accumulation of abnormal collagen fibers and extracellular matrix components by fibroblasts results in the fibrosis of the glandular interstitium [ 5 , 75 ]. These alterations ultimately result in lacrimal gland dysfunction, with consequent aqueous deficient dry eye.…”

Section: Ocular Gvhdmentioning

confidence: 99%

Ophthalmic Manifestations in Patients with Blood Malignancies

Rossi,

Buizza,

Alessio

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until January 2024 and examines the common ocular complications associated with blood cancers. Ocular complications from primary disease include mass effects from ocular adnexal lymphomas and intraocular lymphomas, with B-cell lymphomas accounting for 95% of primary ocular presentations. Secondary disease involvement from systemic hematological malignancies can lead to a wide range of ocular manifestations, such as leukemic retinopathy. Furthermore, toxicity from antineoplastic therapies and ocular graft versus host disease (oGVHD) after hematopoietic stem cell transplantation present additional risks to ocular health. In conclusion, ocular complications in blood cancer patients are an integral part of patient management, requiring regular ophthalmic evaluations and close collaboration between oncologists and ophthalmologists. Advances in therapy and an increased focus on early symptom recognition are essential for preserving vision and enhancing patient quality of life.

show abstract

Section: Ocular Gvhdmentioning

confidence: 99%

Ophthalmic Manifestations in Patients with Blood Malignancies

Rossi,

Buizza,

Alessio

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

show abstract

“…Ocular symptoms of GVHD can include dry eyes, redness, and sensitivity to light. Oral symptoms of GVHD can manifest as painful mouth sores and difficulty in swallowing (80). Gastrointestinal GVHD may lead to diarrhea, abdominal pain, and even malabsorption.…”

Section: Protein Based Biomarkers For Sitespecific Involvement In Gvhdmentioning

confidence: 99%

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Iacobescu,

Pop,

Uifălean

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Despite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified by the occurrence of graft-versus-host disease (GVHD). Risk stratification prior to symptom manifestation, along with precise diagnosis and prognosis, relies heavily on clinical features. A critical imperative is the development of tools capable of early identification and effective management of patients undergoing allo-HSCT. A promising avenue in this pursuit is the utilization of proteomics-based biomarkers obtained from non-invasive biospecimens. This review comprehensively outlines the application of proteomics and proteomics-based biomarkers in GVHD patients. It delves into both single protein markers and protein panels, offering insights into their relevance in acute and chronic GVHD. Furthermore, the review provides a detailed examination of the site-specific involvement of GVHD. In summary, this article explores the potential of proteomics as a tool for timely and accurate intervention in the context of GVHD following allo-HSCT.

show abstract

“…Typical symptoms of dry eye comprise foreign body sensation, photophobia, red eye, photophobia, tearing, ocular fatigue and other ocular discomfort. Thus, oGVHD affects patient's QOL [15][16][17][18] . QOL is defined as the general well-being of individuals and societies [19] .…”

Section: Introductionmentioning

confidence: 99%

Ocular manifestations and quality of life in patients after hematopoietic stem cell transplantation

Fan¹,

Zeng²,

Huang³

et al. 2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To explore the relationship between ocular and systemic conditions and the impact of ocular complications on the quality of life (QOL) in patients after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT). METHODS: Forty-four patients with severe hematopoietic disease were enrolled after ALLO-HSCT at our center from July 2018 to October 2020. They completed two questionnaires: the Ocular Surface Disease Index (OSDI) and the quality-of-life scale for Chinese patients with visual impairment (SQOL-DV1). Ocular conditions and systemic conditions were also assessed. RESULTS: Eye damage was correlated with total bilirubin (P=0.005), and gamma-glutamyl transferase (GGT) (P=0.021). There was no significant correlation between the overall QOL score and OSDI (P=0.8226) or SQOL-DV1 (P=0.9526) scores. The OSDI and the overall QOL score were not correlated with ocular conditions, including best-corrected visual acuity (BCVA), intraocular pressure, Schirmer tear test II, sodium fluorescein staining, tear film breakup time, and tear meniscus height. SQOL-DV1 was correlated with BCVA (P=0.0007), sodium fluorescein staining (P=0.007), and tear film breakup time (P=0.0146). CONCLUSION: In some patients, early ocular symptoms are not evident after ALLO-HSCT, while ocular surface complications can be observed after a comprehensive ophthalmological examination. Especially for those with elevated total bilirubin or GGT, regular ophthalmic follow-up visits are essential to diagnose and treat ocular graft versus host disease (oGVHD), especially for patients with elevated total bilirubin or GGT.

show abstract

Recent advances in ocular graft-versus-host disease

Cited by 8 publications

References 154 publications

Ophthalmic Manifestations in Patients with Blood Malignancies

Ophthalmic Manifestations in Patients with Blood Malignancies

Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants

Ocular manifestations and quality of life in patients after hematopoietic stem cell transplantation

Contact Info

Product

Resources

About